Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has provided an update.
Qyuns Therapeutics Co., Ltd. has announced the advancement of its product QX004N into Phase III clinical trials, marking it as the fourth product in their pipeline to reach this stage. This milestone has triggered a payment of RMB58.0 million from Hansoh Pharma, as per their licensing agreement, which covers the research, development, manufacturing, and commercialization of QX004N in several regions including mainland China and Hong Kong. This development signifies a significant step forward in the company’s operations and strengthens its position in the pharmaceutical industry.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company based in China, focusing on the development of innovative therapeutic products. The company is engaged in the pharmaceutical industry, with a specialization in developing treatments for conditions such as psoriasis and Crohn’s disease. Its primary product in development is QX004N, an interleukin-23 subunit p19 inhibitor.
Average Trading Volume: 285,847
Technical Sentiment Signal: Strong Buy
Find detailed analytics on 2509 stock on TipRanks’ Stock Analysis page.